The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”) hereby informs that on January 10, 2022 the Issuer’s subsidiary – Selvita Inc. received from a biotechnology company based in the United States (the “Customer”) a work order under a framework agreement concluded with the Customer on August 22, 2016 (“Agreement”), the subject of which is to provide support for the Customer’s drug discovery platform in the field of medicinal chemistry, involving synthesis of chemical compounds indicated by the Client.

The value of the work order, which is to be executed over the following 12 months, amounts to USD 4,717,440 (18,899,951.61 PLN converted at the average exchange rate of the National Bank of Poland 1 USD = 4.0064 PLN as of January 10, 2022).

The Issuer’s cooperation with the Customer has been ongoing since 2016, and the Issuer informed about the previous extension of cooperation with the Customer in the current report No. 4/2020 dated 19 February, 2020. The Issuer indicates that the received work order is one of the largest single work orders received by the Issuer to date. Considering the value of the work order, as well as the fact of a notable extension of cooperation with the Client, the Management Board of the Issuer considers the work order to be significant.

Legal basis: Art. 17.1 of MAR
Representatives of the Company:
• Bogusław Sieczkowski – President of the Management Board
• Miłosz Gruca – Vice President of the Management Board